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with algorithm accuracy and sensor reli-
ability.[4] Alternatively, chemically engi-
neered formulations or devices with the 
assistance of glucose oxidase (GOx),[5] 
phenylboronic acid (PBA),[6] and glucose 
binding protein[7] have attracted increasing 
attention.[8] For example, GOx catalyzes 
the oxidation of glucose to gluconic acid 
in the presence of oxygen and generates 
hydrogen peroxide (H2O2).[9] Accordingly, 
GOx-mediated enzymatic reaction can 
create a local oxidative and acidic envi-
ronment triggered by elevated glucose 
levels to promote the release of insulin 
preloaded in acid-responsive systems.[10] 
However, the typical pH change-triggered 
response of materials is often accompa-
nied by slow changes in the conformation 
and morphology of materials and formu-
lations under a physiological condition.[5e] In addition, the in 
vivo release of GOx from medical devices may cause potential 
toxicity,[11] as well as the concerns over long-term biocompat-
ibility of the H2O2 generated during oxidation of glucose.[12] 
Therefore, the ongoing development of smart insulin delivery 
systems is focused on achieving several merits, including rapid 
responsiveness, ease of preparation and administration, as well 
as excellent biocompatibility.[13]
Here, we describe a new glucose-responsive microneedle 
(MN) array patch[14] for self-regulated insulin delivery, uti-
lizing H2O2 and pH cascade-responsive NCs. Briefly, insulin 
was first entrapped into degradable complex micelles (des-
ignated Ins-NCs); while GOx was encapsulated into non-
degradable complex micelles (designated GOx-NCs) via 
crosslinking with uncleavable bonds (Scheme 1a). Both Ins-
NCs and GOx-NCs were then loaded into the crosslinked gel 
core matrix of microneedle. Under a hyperglycemic condi-
tion, the Ins-NCs could respond to H2O2 and gluconic acid 
generated by the GOx-catalyzed oxidation of glucose and be 
dissociated to promote insulin release because of the dis-
ruption of micelle structure as well as charge reductions 
of polymer (positive charge) and insulin (negative charge) 
(Scheme 1a,b). Inspired by the protection function against 
oxidation in the peroxisome,[15] catalase nanogel (CAT-NG)[5b,c]  
was embedded into the crosslinked-poly(vinyl alcohol) (PVA) 
sheath structure, covering the surface of the microneedle core 
matrix (Scheme 1c), to mitigate the injury of H2O2 generated 
in the core part toward normal tissues (Scheme S1, Supporting 
Information). After painless administration of MN patch, 
Self-regulating glucose-responsive insulin delivery systems have great 
potential to improve clinical outcomes and quality of life among patients with 
diabetes. Herein, an H2O2-labile and positively charged amphiphilic diblock 
copolymer is synthesized, which is subsequently used to form nano-sized 
complex micelles (NCs) with insulin and glucose oxidase of pH-tunable nega-
tive charges. Both NCs are loaded into the crosslinked core of a microneedle 
array patch for transcutaneous delivery. The microneedle core is additionally 
coated with a thin sheath structure embedding H2O2-scavenging enzyme to 
mitigate the injury of H2O2 toward normal tissues. The resulting microneedle 
patch can release insulin with rapid responsiveness under hyperglycemic 
conditions owing to an oxidative and acidic environment because of glucose 
oxidation, and can therefore effectively regulate blood glucose levels within 
a normal range on a chemically induced type 1 diabetic mouse model with 
enhanced biocompatibility.
Diabetes mellitus is a global burden affecting 422 million 
people in 2016.[1] It is characterized by a deficit of endogenously 
produced insulin and thereafter elevated blood glucose levels 
(BGLs).[2] Open-loop subcutaneous injection of insulin cannot 
regulate BGLs tightly and is associated with a risk of severe 
hypoglycemia.[3] Thus, a closed-loop system that can “secret” 
desirable amounts of insulin in response to hyperglycemia 
while maintaining basal insulin release kinetics under normo-
glycemia is urgently needed. Electronic closed-loop devices that 
have been developed to this end remain challenges associated 
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Ins-NCs could be decomposed when MN was exposed to elevated 
interstitial fluid glucose under a hyperglycemic state, thereby 
rapidly releasing insulin to capillary vessels and consequently 
restoring homeostasis.
Through the atom transfer radical polymerization (ATRP) ini-
tiated by polyethylene glycolyl monomethyl ether 2-bromoisobu-
tyrate (MPEG5K-Br), 2-(dimethylamino)ethyl methacrylate 
(DMAEMA) was polymerized to obtain MPEG5K-P(DMAEMA)6K 
(Figures S1 and S2a,b, Supporting Information), which was sub-
sequently modified with 4-(bromomethyl)phenylboronic acid 
to obtain the positively charged MPEG5K-P(DMAEMA-PBA)14K 
(Figure S3a,b, Supporting Information). In the presence of 
H2O2, phenylboronic acid on MPEG5K-P(DMAEMA-PBA)14K was 
oxidized and hydrolyzed, generating MPEG5K-P(DMAEMA)6K 
with reduced positive charge (Scheme 1b), as demonstrated by 
1H-NMR (Figure S3a, Supporting Information).[16] In addition, 
poly(DMAEMA) and poly(DMAEMA-PBA) were synthesized 
via ATRP initiated by ethyl α-bromoisobutyrate and subsequent 
quaternarization by 4-(bromomethyl)phenylboronic acid, respec-
tively (Figures S4a,b and S5a,b, Supporting Information). Given 
its isoelectric point of ≈5.3,[17] insulin is negatively charged at pH 
7.4 and capable of complexing with positively charged MPEG5K-
P(DMAEMA-PBA)14K[18] to form Ins-NCs with a PEG corona and 
a complex core.[19] To further stabilize the micelle structure, PVA 
was incorporated via forming acid-inert ester bonds between the 
phenylboronic acids on poly(DMAEMA-PBA) and cis-1, 3-diols on 
PVA.[20] Therefore, Ins-NCs with a loading capacity of 50 wt%, an 
average hydrodynamic size around 60 nm, and ζ-potential of 4.4 
± 0.5 mV were achieved as measured by dynamic light scattering
(DLS) (Figure 1a) and transmission electronic microscopy (TEM)
(Figure 1b).[21] When Ins-NCs were degraded, the solution gradu-
ally became transparent after incubation with glucose (400 mg
dL−1) in the presence of GOx (Figure S6, Supporting Informa-
tion). Meanwhile, GOx was also integrated into m-PVA stabilized
nanocomplex micelles (GOx-NCs) with an average hydrodynamic
size of around 50 nm (Figure S7, Supporting Information) and
Scheme 1. Schematic of the glucose-responsive insulin delivery system utilizing H2O2 and pH cascade-responsive NC-loading MN-array patch. a) For-
mation of Ins-NCs and GOx-NCs and mechanism of glucose-responsive insulin release. b) Schematic of H2O2-triggered charge reduction of the 
polymer. c) Schematic of the NC-containing MN-array patch with a CAT sheath structure for in vivo insulin delivery. Insulin release is triggered under 
a hyperglycemic state.
ζ-potential of 2.1 ± 0.4 mV. In addition, an undegradable net-
work of m-PVA on GOx-NCs formed upon exposure to UV light 
(365 nm, 6 × 10 s). GOx-NCs had a GOx loading capacity of 
33 wt%, and showed similar activity to native GOx regarding cat-
alyzing the oxidation of glucose to produce H2O2 (Figure 1c).[22] 
Furthermore, a different pH value after GOx-NC catalysis indi-
cated a glucose concentration-dependent manner of gluconic 
acid generation (Figure 1d). Next, the insulin release rate was 
evaluated in the presence of GOx in phosphate buffered saline 
(PBS) at pH 7.4 with three different glucose concentrations, 
including a typical hyperglycemic level (400 mg dL−1), a normo-
glycemic level (100 mg dL−1), and a control level (0 mg dL−1). The 
insulin release rate was remarkably promoted under a hypergly-
cemic state compared to those of other two groups (Figure 2a).
Furthermore, the mechanism of glucose-triggered insulin 
release was investigated. Prior to PVA crosslinking, instant 
insulin release was triggered in both 100 and 400 mg dL−1 glu-
cose solution (Figure S8, Supporting Information). However, 
the addition of PVA stabilized the complex and significantly 
reduced insulin release in 100 mg dL−1 glucose solution 
(Figure 2a). Further studies indicated that 
neither H2O2 nor slightly acidic environment 
could individually achieve insulin release 
(Figure 2b). Moreover, insulin was found to 
be instantly released in slightly acidic pH 
from the complex that was pretreated with 
H2O2, indicating that the insulin was released 
in a cascade: (1) poly(DMAEMA-PBA) was 
oxidized and hydrolyzed to poly(DMAEMA), 
leading to reduced positive charge of polymer 
and crosslinking density of Ins-NCs; (2) the 
gradually decreased pH led to reduced nega-
tive charge or even charge reversal of insulin 
(from negative to positive charge under 
pH lower than isoelectronic point), thereby 
resulting in the dissociation of complex and 
subsequent release of insulin. This two-step 
pattern of insulin release endows the insulin 
delivery system enhanced safety for in vivo 
application to avoid the unwanted insulin 
release solely triggered by either H2O2 or 
acid, for example, generated in a nonrelevant 
condition of inflammation.[23] Moreover, the 
release rate of insulin from complex was 
steadily enhanced when gradually increasing 
the glucose concentrations of the tested solu-
tions from normoglycemic to hyperglycemic 
conditions, where a 50-fold difference in 
insulin release rate was achieved in 1 h when 
the glucose concentration was increased 
from 100 to 400 mg dL−1 (Figure S9, Sup-
porting Information). Additionally, the pul-
satile release profile of insulin was achieved 
when the complex was alternatively exposed 
to the normoglycemic and hyperglycemic 
levels (Figure S10, Supporting Information).
The insulin and GOx release profiles from 
nanocomplex micelles encapsulated in m-PVA 
gel were critical for their in vivo applica-
tion. The m-PVA gel was prepared from m-PVA aqueous solu-
tion via exposure to UV light in the presence of a radical ini-
tiator (Figure S11, Supporting Information). The release rate of 
insulin from Ins-NCs entrapped in the gel was twofold faster at 
a glucose concentration of 400 mg dL−1 than that of 100 mg dL−1 
(Figure 2c). Meanwhile, the release rate of GOx was independent 
on glucose level and occurred in negligible amounts due to the 
crosslinking of GOx-NCs by m-PVA (Figure 2d). Additionally, 
the far-UV circular dichroism spectra of the native and released 
insulin from gels were nearly identical, suggesting that the 
released insulin retained α-helical secondary structure associated 
with bioactivity (Figure S12, Supporting Information).
To facilitate the administration, Ins-NCs and GOx-NCs were 
integrated into an MN array patch. The MN array patch was pre-
pared using a micromolding approach. First, the CAT was encap-
sulated into a CAT-NG (Figure S13, Supporting Information) to 
inhibit passive release of CAT.[5b] CAT-NG retained the activity of 
catalyzing H2O2 to H2O (Figure S14, Supporting Information), 
and was then dissolved in an aqueous solution containing m-
PVA and photoinitiator, loaded into a silicone micromold, and 
Figure 1. Characterizations of Ins-NCs and GOx-NCs. a) Representative image of Ins-NC solu-
tion and hydrodynamic size distribution of Ins-NCs as determined by DLS. Inset: A representa-
tive picture of the Ins-NC solution sample (insulin concentration: 1 mg mL−1). b) Representative 
TEM image of Ins-NCs. Scale bar, 100 nm. c) H2O2 generation in PBS (10 × 10−3 m, pH 7.4)
containing glucose (400 mg dL−1) as catalyzed by GOx and GOx-NCs. d) The pH change of PBS 
solution of various glucose concentrations (100 or 400 mg dL−1) in the presence of GOx-NCs 
(0.2 mg mL−1 GOx-eq. concentration). Data points represent mean ± SD (n = 3). Error bars 
indicate SD.
Figure 2. In vitro characterization of glucose-responsive insulin release. a) Glucose concentration-dependent insulin release from a complex of insulin 
in PBS 7.4 in the presence of GOx (0.2 mg mL−1). The glucose concentration was set as 0, 100, and 400 mg dL−1. b) H2O2 (5 × 10−3 m) and pH cascade-
triggered insulin release from a complex of insulin. c) Glucose concentration-dependent insulin release from Ins-NCs loaded in m-PVA gel in PBS 7.4 in the 
presence of GOx (0.2 mg mL−1). d) Glucose concentration-dependent GOx release from GOx-NCs encapsulated in m-PVA gel in PBS 7.4. Additional GOx 
(0.2 mg mL−1) was added. The glucose concentration was set as 100 and 400 mg dL−1. Data points represent mean ± SD (n = 3). Error bars indicate SD.
Figure 3. Characterization of the MN array patch with a sheath structure. a) Representative scanning electron microscopy (SEM) image of microneedle 
array patch. Scale bar, 600 µm. b) Representative fluorescence microscopy image of MN arrays loaded with rhodamine B-labeled insulin. Scale bar, 
600 µm. c) Representative images of a cross-section of MN with a CAT-NG sheath:rhodamine B-labeled insulin (red), FITC-labeled CAT sheath layer 
(green), and merging of both images. The sheath layer was 23 ± 6 µm thick as analyzed using software ImageJ. Scale bar, 100 µm.
kept under reduced pressure for 30 min. After centrifugation, 
it was exposed to UV light (6 × 10 s) to crosslink the matrix to 
form an MN “sheath.” Ins-NCs, GOx-NCs, and radical initiator 
dissolved in an aqueous solution containing PVA/m-PVA and 
polyvinylpyrrolidone (PVP) were then depo sited in silicone 
molds to form an MN “core”. The addition of a proper ratio of 
PVP has been shown to enhance the strength of microneedle 
for better skin penetration.[24] The resulting device was arranged 
in a 20 × 20 MN array on a patch. The needle had a conical 
shape (Figure 3a,b) and enough strength (Figure S15, Sup-
porting Information).[25] In addition, fluorescein isothiocyanate 
(FITC)-labeled CAT-NG formed a sheath covering the PVA/m-
PVA/PVP core loaded with the rhodamine B-labeled insulin as 
validated using fluorescence microscope (Figure 3c).
The in vivo performance of the MN array patches was evalu-
ated utilizing a mouse model of type 1 diabetes induced by strep-
tozotocin. The mice were divided into four groups treated with 
(1) CAT-NG-coated MN array patch loaded with GOx-NCs and
Ins-NCs (MN-(G+C+I)); (2) subcutaneous injection of human
recombinant insulin; (3) microneedle array patch loaded with
blank PVA/m-PVA and PVP (MN-Gel); and (4) CAT-NG-coated
MN array patch of Ins-NCs (MN-(C+I)). The staining by trypan
Figure 4. In vivo evaluation of MN array patches for type 1 diabetes treatment. a) Blood glucose levels of type 1 diabetic mice treated with various 
kinds of microneedle array patches. b) Blood insulin level of mice treated with MN array patches. Data points represent mean ± SD (n = 3). *P < 0.05, 
**P < 0.01 (analyzed by two-tailed Student’s t-test) for MN-(G+C+I) compared with control MN-(C+I). c) Representative images of skins at the treated 
site of mice. Mice were treated with MN-Gel, MN-(G+I), and MN-(G+C+I) for 12 h, and the skins were gathered after the mice were euthanized. Scale 
bars, 1 cm. d) H&E staining and immunohistologic staining with TUNEL assay (green) and Hoechst (blue) of skins treated with MN-(G+C+I). Scale 
bars, 300 µm. e) Analysis of blood white cells of mice treated with MN-(G+C+I). Blood samples were obtained 2 d post-treatment. WBC: white blood 
cells; NEUT: neutrophils; LYMPH: lymphocytes; MONO:  monocytes; EO: eosinophils; BASO:  basophils.
blue indicated successful penetration of MNs into the excised 
skin (Figure S16, Supporting Information). Besides, the temporal 
microchannels on the skin caused by MNs could quickly recover 
within 2 h post-treatment (Figure S17, Supporting Information).
BGLs of the mice were monitored over time following treat-
ment with MN patches. It was observed that the BGLs of mice 
treated by MN-(G+C+I) were quickly decreased to around 
100 mg dL−1 in 30 min post-administration and maintained 
below 200 mg dL−1 for almost 4 h, considerably longer than those 
of the mice subcutaneously injected with insulin (Figure 4a). 
This fast dynamic in BGL change was attributed to the rapid 
establishment of the local oxidative and acidic environment 
through oxidation of glucose absorbed from interstitial fluid, 
which has a similar glucose level to that in blood,[26] as well as 
the high sensitivity of Ins-NCs to these stimuli. In contrast, the 
negligible BGL reduction was observed in the mice treated with 
MN-(C+I) and MN-Gel. Additionally, the plasma human insulin 
levels in mice treated with MN-(G+C+I) were significantly 
higher than those treated with MN-(C+I) (Figure 4b).
Moreover, the intraperitoneal glucose tolerance test was car-
ried out 1 h post-administration of MNs or insulin. A spike in 
BGLs was observed for all groups after the intraperitoneal injec-
tion of glucose. However, only healthy mice and MN-(G+C+I) 
could restore blood glucose levels to a normoglycemic level 
within a short period, and the mice treated with MN-(G+C+I) 
showed significantly enhanced glucose tolerance to the glucose 
challenge (Figure S18, Supporting Information). To assess the 
risk of hypoglycemia associated with treatment by MN-(G+C+I), 
the BGLs of healthy mice treated with different MN array patches 
were observed. The BGLs of mice treated with insulin showed 
a remarkable decrease, while the BGLs of mice treated with 
MN-(G+C+I) showed only a slight decrease, consistent with the 
slow release of insulin from gels under a normoglycemic state 
(Figure S19a, Supporting Information). Additionally, the MN-
(G+C+I)-treated group showed significantly lower hypoglycemia 
index than insulin (Figure S19b, Supporting Information).
Importantly, the matrix materials used for insulin delivery 
have shown negligible in vitro cytotoxicity (Figure S20, Sup-
porting Information). For in vivo toxicity, compared to the skin 
tissues treated by MN-Gel (Figure 4c), a clear damage of skin 
tissue was observed for MN-(G+I). In sharp contrast, only neg-
ligible inflammation was observed on the skin of mice treated 
with MN-(G+C+I) due to the presence of a CAT-embedded sheath 
(Figure 4c). These findings were further validated by hematoxylin 
and eosin (H&E) staining results. Compared with the skin treated 
with MN-Gel (Figure S21, Supporting Information), the skin 
samples treated with MN-(G+I) (Figure S21, Supporting Infor-
mation) were significantly thicker and showed apparent neutro-
phil infiltration, indicating a pathophysiological response and 
tissue damage induced by H2O2.[27] However, reduced neutrophil 
infiltration was observed in skin samples from mice treated with 
MN-(G+C+I) (Figure 4d). Additionally, the skin tissue stained 
with the in situ terminal deoxynucleotidyl transferase deoxyu-
ridine triphosphate (dUTP) nick end labeling (TUNEL) assay 
clearly demonstrated the negligible cell apoptosis in the skin 
sample treated with MN-(G+C+I) as compared to that associated 
with the control group (Figure 4d and Figure S21, Supporting 
Information). Accordingly, the counts of white blood cells from 
mice treated by MN-(G+C+I) were similar to that of the healthy 
mice (Figure 4e). For the long-term usage, the frequent exposure 
of skin tissues to the leaking H2O2 could cause some side effects. 
However, with the optimization of the ratio of CAT and GOx, as 
well as regular change of the MN administration position, the 
side effects toward skin could be minimized for daily usage. The 
animal study protocol was approved by the Institutional Animal 
Care and Use Committee at North Carolina State University and 
the University of North Carolina at Chapel Hill.
In summary, we have developed a new MN-array patch 
with a sheath structure, loaded with dual sequential stimuli-
responsive nanocomplex micelles for self-regulated insulin 
delivery. It was demonstrated that this patch could rapidly and 
safely release insulin triggered by locally generated H2O2 and 
an acidic microenvironment under a hyperglycemic condition. 
In vivo experiments indicated that the MN-(G+C+I) was effec-
tive in regulating BGLs under a normoglycemic state while 
reducing the risk of hypoglycemia. Importantly, utilization of 
CAT sheath-like coating significantly mitigated the skin inflam-
mation caused by the production of H2O2.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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